**Supplementary Table S1. RACIN phase I study: dose limiting toxicities definitions**

|  |  |
| --- | --- |
| DLTs group A (all study treatments) | Grade 4-5 allergic reactions related to the infusion, extending for ≥2 hours after infusion, not reversible to grade≤2 within 24 hours of infusion administration with standard therapy |
| Grade ≥4 autoimmune reactions |
| Grade ≥4 major organ toxicity (cardiac, pulmonary, hepatic, renal, neurological) not pre-existing and not related to the underlying malignancy, not resolving to grade ≤ 2 within 14 days. |
| Any AEs related to the drug combination leading to permanent discontinuation of treatment. |
| DLT group B belonging to cyclophosphamide  | Grade ≥4 neutropenia (ANC < 500/µL)  |
|  | Grade ≥3 febrile neutropenia lasting ≥ 10 days  |
|  | Grade ≥4 thrombocytopenia lasting > 5 days |
|  | Any AEs related cyclophosphamide leading to permanent discontinuation of treatment. |
| DLT group C belonging to aspirin | Grade ≥2 hemorrhagic episodes |
|  | Grade ≥2 gastritis or peptic ulcer  |
|  | Any AEs related aspirin leading to permanent discontinuation of treatment. |
| DLT group D belonging to low dose irradiation | Grade >3 local reaction that appears inside the irradiated volume (i.e., esophagitis if the esophagus was in the treatment field) |

Abbreviations: DLT: dose limiting toxicity, AE: adverse event, ANC: absolute neutrophil count.